Antagonistic monoclonal antibodies and small-molecule inhibitors of receptor tyrosine kinases or intracellular pro-survival pathways can lower the apoptotic threshold and thus increase the tumour-specific cytotoxicity of chemotherapeutics. This evidence concerns the gene NTRK1 and neoplasm.